북미의 단위 용량 제조 시장 규모, 점유율, 동향 분석 보고서 : 조달처별, 제품별, 최종 용도별, 국가별, 지역별, 부문별 예측(2025-2030년)

North America Unit Dose Manufacturing Market Growth & Trends:

The North America unit dose manufacturing market size is expected to reach USD 56.22 billion in 2030 and is projected to grow at a CAGR of 11.23% from 2025 to 2030. The rapidly growing pharmaceutical industry and rising demand for unit doses are factors driving the market.

Single-dose packaging has certainly become one of the most popular recent trends. The most obvious benefit is its ease of use and improved medication management, as they can be prescribed by the unit, ensuring that the person taking it does not exceed the prescribed dose. Stick packs are unique in the way that they can be used to package a variety of items, both dry and wet.

Measuring cups, teaspoons, tablespoons, and multi-dose containers for oral liquids and eye drops have been already seen. The current patient is seeking convenience. Doctors are also appreciating the importance of unit dose in prescription writing since it allows them to prescribe controlled substance oral liquid without concern of abuse as unit doses address the issue. It also enables pharmacists to store oral liquids in a secure manner, which is a significant additional benefit. Nearly every single unit dose oral solid or multiple-dose oral liquid could be transformed to a unit dose oral liquid due to this innovation.

However, owing to the COVID-19 pandemic's repercussions, the unit dose manufacturing market increased at a modest 11.0% year over year in 2020. By the end of 2020, the market started to recover. COVID-19-related illnesses are being treated using unit dosages. Hospitals have updated and implemented various new standard operating procedures to protect both patients and healthcare workers. As a consequence, it's crucial to consider out viral transmission by airborne transmission or direct contact. When unit dose medicines are used, some of the risks involved with handling and pouring doses from the same bottle are reduced.

North America Unit Dose Manufacturing Market Report Highlights:

• The outsourcing segment led the market with the largest revenue share of 60.13% in 2024. Unit doses lead to the minimization of credits for drugs coupled with greater control by a pharmacist over work patterns and schedules.
• The solid unit dose segment led the market with the largest revenue share of 49.71% in 2024. In 2018, oral solid dosage medicines accounted for 53% of all new pharmaceuticals approved by the FDA.
• The independent pharmacies segment led the market with the largest revenue share of 37.83% in 2024.
• The hospitals segment accounted for the second-largest revenue share in 2024. Unit dose packaging ensures precise dosing, reduces the possibility of medication errors, and supports medication safety protocols within hospital settings.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. North America Unit Dose Manufacturing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increased Adoption of Unit Doses
    • 3.2.1.2. Benefits of Manufacturing Unit Doses Over Repackaging
    • 3.2.1.3. Growing Outsourcing Activities
    • 3.2.1.4. Technological Advancements in Unit Dose Manufacturing
    • 3.2.1.5. Increasing Prevalence of Chronic Diseases and Demand for Personalized Medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Challenges Associated with the Adoption of Manufactured Unit Doses
    • 3.2.2.2. Compliance Issues with Outsourcing
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. North America Unit Dose Manufacturing Market: Sourcing Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. North America Unit Dose Manufacturing Market: Sourcing Movement Analysis
• 4.3. North America Unit Dose Manufacturing Market Estimates & Forecasts, by Sourcing, 2018 - 2030 (USD Million)
• 4.4. In-House
  • 4.4.1. In-House Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 4.5. Outsourcing
  • 4.5.1. Outsourcing Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Unit Dose Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. North America Unit Dose Manufacturing Market: Product Movement Analysis
• 5.3. North America Unit Dose Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
• 5.4. Liquid Unit Dose
  • 5.4.1. Liquid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 5.5. Solid Unit Dose
  • 5.5.1. Solid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Unit Dose Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. North America Unit Dose Manufacturing Market: End Use Movement Analysis
• 6.3. North America Unit Dose Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
• 6.4. Independent Pharmacies
  • 6.4.1. Independent Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 6.5. Long Term Care Facility
  • 6.5.1. Long Term Care Facility Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospitals Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 7. North America Unit Dose Manufacturing Market: Country Estimates & Trend Analysis, by Sourcing, by Product, By End Use

• 7.1. Country Dashboard
• 7.2. Country Movement Analysis
• 7.3. North America
  • 7.3.1. North America Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Unit Dose Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Catalent Inc.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Unither Pharmaceuticals
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Thermo Fisher Scientific
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Corden Pharma
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Mikart
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Tape Mark
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Renaissance Lakewood LLC
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Medical Packaging Inc
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. American Health Packaging
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. PCI Pharma Services
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Amcor PLC
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Bristol-Myers Squibb
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. AbbVie Inc.
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives
  • 8.3.14. Merck & Co. Inc.
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Service Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15. Pfizer Inc.
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Service Benchmarking
    • 8.3.15.4. Strategic Initiatives